The FDA Approved FluMist (AstraZeneca) will be self-administered by adult patients up to 49 years old, or administered by caregivers for children between 2 and 17...
AstraZeneca’s FluMist Quadrivalent Seeks FDA Approval for Self-Administration The FDA has accepted AstraZeneca’s its application for review, seeking approval for patients or caregivers to administer its...
Mayuresh Abhyankar, a researcher at the University of Virginia who studies infectious diseases and works on nasal vaccines, says there are many immunological benefits to vaccination...
Recent Comments